Cargando…

The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis

BACKGROUND: Cladribine is a useful therapeutic option in RRMS with moderate to high disease activity. Its oral formulation and tolerability make it a useful alternative to infusion therapies. Cladribine is known to deplete CD19(+) B lymphocytes, but its effect on immunoglobulin subsets is unclear. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lycett, Mitchell J, Lea, Rodney A, Maltby, Vicki E, Min, Myintzu, Lechner-Scott, Jeannette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830094/ https://www.ncbi.nlm.nih.gov/pubmed/36636583 http://dx.doi.org/10.1177/20552173221149688

Ejemplares similares

DNA methylation changes in CD4(+) T cells isolated from multiple sclerosis patients on dimethyl fumarate
por: Maltby, Vicki E, et al.
Publicado: (2018)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
por: Maltby, Vicki E, et al.
Publicado: (2021)

Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes
por: Groen, Kira, et al.
Publicado: (2020)

Erythrocytes in multiple sclerosis – forgotten contributors to the pathophysiology?
por: Groen, Kira, et al.
Publicado: (2016)

Differential methylation at MHC in CD4(+) T cells is associated with multiple sclerosis independently of HLA-DRB1
por: Maltby, Vicki E., et al.
Publicado: (2017)

Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis
por: Groen, Kira, et al.
Publicado: (2018)

Genome-wide DNA methylation changes in CD19(+) B cells from relapsing-remitting multiple sclerosis patients
por: Maltby, Vicki E., et al.
Publicado: (2018)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity
por: Campagna, Maria Pia, et al.
Publicado: (2022)

Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients
por: Maltby, Vicki E., et al.
Publicado: (2015)

Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells
por: Sanders, Katherine A., et al.
Publicado: (2016)

Letter to the editor: blood processing and sample storage have negligible effects on methylation
por: Groen, Kira, et al.
Publicado: (2018)

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy
por: Lizak, Nathaniel, et al.
Publicado: (2020)

Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis
por: Campagna, Maria Pia, et al.
Publicado: (2023)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients
por: Maltby, Vicki E., et al.
Publicado: (2020)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
por: Maltby, Vicki, et al.
Publicado: (2023)

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
por: Brochet, Bruno, et al.
Publicado: (2023)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS?
por: Bateman, Grant A., et al.
Publicado: (2016)

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
por: Spelman, Tim, et al.
Publicado: (2022)

Capturing SNP Association across the NK Receptor and HLA Gene Regions in Multiple Sclerosis by Targeted Penalised Regression Models
por: Burnard, Sean M., et al.
Publicado: (2021)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes
por: Xavier, Alexandre, et al.
Publicado: (2023)

2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multiple sclerosis
por: Quadrelli, Scott, et al.
Publicado: (2019)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020)

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5lrs55jjh5u7g3bbjb2llo9igb